



**HAL**  
open science

## Care for uterine fibroids: another casualty of the COVID pandemic

Saad Zbiri, Arnaud Fauconnier, Carine Milcent

► **To cite this version:**

Saad Zbiri, Arnaud Fauconnier, Carine Milcent. Care for uterine fibroids: another casualty of the COVID pandemic. *BJOG: An International Journal of Obstetrics and Gynaecology*, 2023, 10.1111/1471-0528.17293 . halshs-03812609

**HAL Id: halshs-03812609**

**<https://shs.hal.science/halshs-03812609>**

Submitted on 12 Oct 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Care for uterine fibroids: another casualty of the COVID**  
2 **pandemic**

3  
4 Saad Zbiri<sup>1\*</sup>; Arnaud Fauconnier<sup>1,2</sup>; Carine Milcent<sup>3,4\*</sup>

5  
6 <sup>1</sup> Research Unit 7285 “Risk and Safety in Clinical Medicine for Women and Perinatal Health”  
7 (RISCQ), UVSQ, Paris-Saclay University, Montigny-le-Bretonneux, France

8 <sup>2</sup> Department of Obstetrics and Gynecology, Poissy Saint-Germain Hospital, Poissy, France

9 <sup>3</sup> Paris-Jourdan Sciences Economiques, French National Center for Scientific Research  
10 (CNRS), Paris, France

11 <sup>4</sup> Paris School of Economics (PSE), Paris, France

12  
13 **\* Corresponding author:**

14 48 boulevard Jourdan, 75014, Paris, France

15 E-mail: carine.milcent@psemail.eu (CM), saad.zbiri3@uvsq.fr (SZ)

16 Phone: + 33 1 80 52 19 08

17  
18 **Shortened running title:** Uterine fibroids during COVID-19 pandemic

19  
20 **Keywords:** Uterine fibroid; COVID-19; Health policy; Population health; Healthcare access

24 **Care for uterine fibroids: another casualty of the COVID**  
25 **pandemic**

26 Saad Zbiri<sup>1\*</sup>; Arnaud Fauconnier<sup>1,2</sup>; Carine Milcent<sup>3,4\*</sup>

27 **Abstract**

28 Overall, during the COVID-19 pandemic, a large proportion of uterine fibroids were not  
29 managed in the hospital setting. The lockdown period was associated with large reductions in  
30 hospital service utilisation, particularly for non-emergency patients. As we observed no short-  
31 term post-lockdown catch-up, two questions arise: What became of these untreated patients?  
32 How has their future health been affected? Two hypotheses appear likely. The first is that the  
33 woman continued receiving outpatient care, but the therapeutic procedures took place only in  
34 hospitals and there were fewer of them. While medical treatment could theoretically have  
35 been used, the only available treatment was removed from the market in March 2020 due to  
36 the risk of serious drug-induced hepatitis. The second is that of non-recourse to care, or its  
37 deferral for more than a year, or even therapeutic abstention because no kind of treatment was  
38 available. This strongly suggests a loss of opportunity for these women, with its  
39 accompanying risks of hysterectomy, of transfusions, and of impaired quality of life.

40

41

# Care for uterine fibroids: another casualty of the COVID pandemic

Saad Zbiri<sup>1\*</sup>; Arnaud Fauconnier<sup>1,2</sup>; Carine Milcent<sup>3,4\*</sup>

Uterine fibroids are the most common benign tumours in women (1,2). The main consequences of uterine fibroids are menorrhagia and pelvic pain with the risk of complications related to uterine haemorrhage. Because treatment is mainly surgical or by embolization, it generally takes place in hospitals. Gonadotrophin-releasing hormone (GnRH) agonist treatment temporarily reduces fibroids, but its long-term use is unsafe (1,2). The European Medicines Agency suspended ulipristal acetate, the pharmaceutical treatment, from the market in March 2020 (3). Simultaneously, the new coronavirus disease 2019 (COVID-19) rapidly became a global pandemic (4). Governments have had to make difficult trade-offs to contain its spread (5). We used French national hospitalization data to explore variations in admissions of patients admitted with uterine fibroids in 2019 (reference year) and 2020. We considered four distinct periods during 2020 corresponding to different phases of the pandemic. We then discuss the impact of policy responses to COVID-19 on patients' access to care and health outcomes.

Figure 1 shows, as expected, no change in the number of admissions during the pre-health crisis period. The number then fell sharply after the lockdown decision. By the in-between period, it had begun to recover, returning to trace the pre-crisis distribution without catching up for the 2020 decrease already observed. Overall, over 2020, the number of admissions for

65 uterine fibroids dropped by about 14%. The variation in the rate of emergency admissions  
66 (Figure S1 in the Appendix) indicates that women admitted during the lockdown period were  
67 mainly those whose condition was relatively urgent. This result raises the question of the  
68 management received by women who did not present an imminent emergency situation but  
69 who normally used hospital services in non-crisis periods. Finally, the rates of anaemia and  
70 transfusion (Figures S2 and S3 in the Appendix) in these patients rose substantially during the  
71 lockdown period, compared with 2019; these higher rates persisted during the in-between  
72 period. This finding shows that women who were hospitalised were the most severely ill and  
73 brings us back to Figure 1's illustration of a major decrease in hospital admissions during the  
74 lockdown. The women admitted to hospitals were evidently those with complications.

75 Overall, during the COVID-19 pandemic, a large proportion of uterine fibroids were not  
76 managed in the hospital setting. The lockdown period was associated with large reductions in  
77 hospital service utilisation, particularly for non-emergency patients. The lockdown measures  
78 encouraged, even required, people to stay at home, to limit viral transmission and especially  
79 to avoid overloading hospitals. This raises the question of patient healthcare-seeking  
80 behaviour given care needs, which the higher complication and emergency admission rates  
81 suggest had not changed. As we observed no short-term post-lockdown catch-up, two  
82 questions arise: What became of these untreated patients? How has their future health been  
83 affected?

84 Two hypotheses appear likely. The first is that the woman continued receiving outpatient care,  
85 but the therapeutic procedures took place only in hospitals and there were fewer of them (2).  
86 While medical treatment could theoretically have been used, the only available treatment,  
87 ulipristal acetate, was removed from the market in March 2020 due to the risk of serious drug-  
88 induced hepatitis (3). The second is that of non-recourse to care, or its deferral for more than a  
89 year, or even therapeutic abstention because no kind of treatment was available. This strongly

90 suggests a loss of opportunity for these women, with its accompanying risks of hysterectomy,  
91 of transfusions, and of impaired quality of life. Future health policy initiatives need to ensure  
92 that nationwide limitations do not adversely affect patient health. Further research is needed  
93 to examine the real impact of such policy measures on population health.

94

95

96

97

98


99 **References**

100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145

1. Stewart EA. Uterine fibroids. *Lancet*. 2001 Jan 27;357(9252):293–8.
2. Lumsden MA, Hamoodi I, Gupta J, Hickey M. Fibroids: diagnosis and management. *BMJ*. 2015 Oct 13;351:h4887.
3. Rozenberg S, Revercez P, Fastrez M, Vandromme J, Bucella D. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA’s review of liver injury risk: Unfortunate timing during the Covid-19 pandemic! *Eur J Obstet Gynecol Reprod Biol*. 2020 Sep;252:300–2.
4. Cash R, Patel V. Has COVID-19 subverted global health? *The Lancet*. 2020 May 30;395(10238):1687–8.
5. Parodi SM, Liu VX. From Containment to Mitigation of COVID-19 in the US. *JAMA*. 2020 Apr 21;323(15):1441–2.

This article has a Video Abstract presented by Saad Zbiri.

146 **Figure 1:** Evolution of the number of inpatients admitted for uterine fibroid per week in  
 147 France in 2019 versus 2020  
 148



149  
 150  
 151 Source: French National Acute Care Hospital Discharge Diagnosis Databases (PMSI-MCO), exhaustive and  
 152 consolidated administrative database, 2019-2020.  
 153 Note: The study population (112 336 women) was selected in accordance with the literature by the appropriate  
 154 codes of the International Classification of Diseases, 10th revision (ICD-10): D250, D251, D252, and D259,  
 155 showing data for 2019 (blue, no lockdown) and 2020 (red, lockdown periods highlighted in grey). Stays are  
 156 considered according to the week of admission. Four periods are distinguished: the pre-sanitary crisis period  
 157 from 01/01/2020 to 16/03/2020, the lockdown period from 17/03/2020 to 09/05/2020, the “in between” period  
 158 from 10/05/2020 to 15/11/2020, and the shutdown period from 16/11/2020 to 17/12/2020.

159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179



180 **Disclosure of Interests**

181 The authors declare that they have no competing interests.

182

183 **Contribution to Authorship**

184 CM analyzed the data, SZ wrote up the manuscript and AF edited the manuscript.

185

186 **Details of Ethics Approval**

187 Data used for this study are reported to the National Data Protection Authority. Informed

188 consent and ethics approval are not required, since the study was based on routinely collected

189 de-identified administrative data, as regulated by French law.

190

191 **Funding**

192 The authors received no funding for this work.

193

194 **Data Availability Statement**

195 The data that support the findings of this study are available from *Agence Technique*

196 *d'Information Hospitalière* (ATIH) Digital. Restrictions apply to the availability of these data,

197 which were used under license for this study.

198

199 **Consent for Publication**

200 All authors reviewed and approved the final manuscript.

201

202

203

204